1
|
Palaia I, Caruso G, Di Donato V, Vestri A, Napoli A, Perniola G, Casinelli M, Alunni Fegatelli D, Campagna R, Tomao F, D’Aniello D, Antonelli G, Muzii L. Pfizer-BioNTech COVID-19 Vaccine in Gynecologic Oncology Patients: A Prospective Cohort Study. Vaccines (Basel) 2021; 10:vaccines10010012. [PMID: 35062673 PMCID: PMC8780883 DOI: 10.3390/vaccines10010012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Revised: 12/20/2021] [Accepted: 12/21/2021] [Indexed: 12/26/2022] Open
Abstract
Objective: To evaluate the safety and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in gynecologic oncology patients under chemotherapy. Methods: A prospective cohort study including gynecologic oncology women who were under chemotherapy or had completed it within 6 months at the time of the study. All patients received a two-dose schedule of the Pfizer-BioNTech COVID-19 vaccine. Results were compared with a control group of healthy women vaccinated in the same period. Results: Overall, 44 oncologic patients with a mean age of 61.3 ± 10.7 years were enrolled: 28 (63.6%) had ovarian cancer, 9 (20.4%) endometrial, and 7 (16%) cervical. The IgG antibody titer after 1 month from vaccination was low in 9 (20.5%) patients, moderate in 21 (47.7%), and high in 14 (31.8%). The 3-month titer was null in 2 (4.5%) patients, low in 26 (59.1%), moderate in 13 (29.5%), and high in 3 (6.8%). Patients ≥ 50 years reported lower 1-month (p = 0.018) and 3-month (p = 0.004) titers compared with <50 years. Patients with BMI < 30 kg/m2 had a higher 1-month titer compared with BMI ≥ 30 kg/m2 (p = 0.016). Compared with healthy women (n = 44), oncologic patients showed a lower 3-month titer (p < 0.001). None of the patients experienced serious adverse effects. Conclusions: The COVID-19 vaccine was safe and immunogenic in gynecologic oncology patients under chemotherapy. Serological monitoring and further vaccine shots should be considered to boost protection.
Collapse
Affiliation(s)
- Innocenza Palaia
- Department of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy; (I.P.); (V.D.D.); (G.P.); (F.T.); (D.D.); (L.M.)
| | - Giuseppe Caruso
- Department of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy; (I.P.); (V.D.D.); (G.P.); (F.T.); (D.D.); (L.M.)
- Correspondence:
| | - Violante Di Donato
- Department of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy; (I.P.); (V.D.D.); (G.P.); (F.T.); (D.D.); (L.M.)
| | - Annarita Vestri
- Department of Public Health and Infectious Diseases, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy; (A.V.); (D.A.F.)
| | - Anna Napoli
- Department of Molecular Medicine, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy; (A.N.); (M.C.); (R.C.); (G.A.)
| | - Giorgia Perniola
- Department of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy; (I.P.); (V.D.D.); (G.P.); (F.T.); (D.D.); (L.M.)
| | - Matteo Casinelli
- Department of Molecular Medicine, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy; (A.N.); (M.C.); (R.C.); (G.A.)
| | - Danilo Alunni Fegatelli
- Department of Public Health and Infectious Diseases, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy; (A.V.); (D.A.F.)
| | - Roberta Campagna
- Department of Molecular Medicine, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy; (A.N.); (M.C.); (R.C.); (G.A.)
| | - Federica Tomao
- Department of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy; (I.P.); (V.D.D.); (G.P.); (F.T.); (D.D.); (L.M.)
| | - Debora D’Aniello
- Department of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy; (I.P.); (V.D.D.); (G.P.); (F.T.); (D.D.); (L.M.)
| | - Guido Antonelli
- Department of Molecular Medicine, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy; (A.N.); (M.C.); (R.C.); (G.A.)
| | - Ludovico Muzii
- Department of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy; (I.P.); (V.D.D.); (G.P.); (F.T.); (D.D.); (L.M.)
| |
Collapse
|